Neurogene Raises $68.5 Million in Series A Financing to Advance Multiple Programs in Devastating Neurological Diseases Proceeds support a product pipeline with multiple AAV-based gene therapies with disease-modifying potential and creation of a company-owned AAV manufacturing facility NEW YORK, February 12, 2019-- Neurogene, Inc., a company founded with a mission to bring life-changing medicines to patients and families affected by rare neurological diseases, today announced a $68.5 million Series A financing. Investors included Samsara BioCapital, EcorR1 Capital, Cormorant Asset Management, Redmile Group and an undisclosed leading healthcare investment fund.